loading page

Adoptive Transfer of Immunomodulatory M2 Macrophages Suppresses Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice via Blockading NF-κb Pathway
  • +4
  • Mingchao Shi,
  • Fengna Chu,
  • Yue Lang,
  • Chao Zheng,
  • Tao Jin,
  • Li Cui,
  • Jie Zhu
Mingchao Shi
Jilin University First Hospital
Author Profile
Fengna Chu
Jilin University First Hospital
Author Profile
Yue Lang
Jilin University First Hospital
Author Profile
Chao Zheng
First Hospital of Jilin University
Author Profile
Tao Jin
First Hospital of Jilin University
Author Profile
Li Cui
Jilin University First Hospital
Author Profile
Jie Zhu
Jilin University First Hospital
Author Profile

Abstract

Objectives: The aims of the study were to further elucidate the roles of M1 and M2 macrophages in the pathogenesis of EAE and the effects of treatment with M2 macrophages that target certain pro-inflammatory cytokines and with immunomodulatory preparations that beneficially influence the disease course should be in focus of future therapeutic trials. Results: Enhanced the total number of macrophages at the onset of clinical signs in the EAE group, consistent with an increased proportion of M1 cells and low numbers of M2 cells. As the disease progressed and the symptoms worsened, M1 cells were decreased and M2 cells were gradually increased till the peak. In the recovery stage, M2 cell numbers were gradually decreased. Treatment with M2 macrophages inhibited the NF-κb pathway, alleviated the symptoms of EAE, reduced inflammatory cell infiltration and demyelination in the central nervous system, and decreased the numbers of macrophages in the spleens. BAY-11-7082, an NF-κb blocking agent, could reduce the total number of macrophages both in vivo and in vitro, effectively prevented the EAE development, and significantly inhibited the symptoms EAE in mice. Conclusions: Macrophages may play a crucial role in the pathogenesis of EAE, while M2 macrophages have anti-inflammatory effects. Transfer of M2 macrophages to EAE mice can block the NF-κb pathway successfully and relieve the EAE symptoms. Application of NF-κb blockers is useful in the prevention and treatment of EAE.

Peer review status:ACCEPTED

04 Sep 2020Submitted to Clinical & Experimental Immunology
04 Sep 2020Submission Checks Completed
04 Sep 2020Assigned to Editor
28 Sep 2020Reviewer(s) Assigned
13 Oct 2020Review(s) Completed, Editorial Evaluation Pending
14 Oct 2020Editorial Decision: Revise Minor
15 Oct 20201st Revision Received
15 Oct 2020Reviewer(s) Assigned
31 Oct 2020Review(s) Completed, Editorial Evaluation Pending
02 Nov 2020Editorial Decision: Revise Major
24 Nov 20202nd Revision Received
24 Nov 2020Reviewer(s) Assigned
28 Nov 2020Review(s) Completed, Editorial Evaluation Pending
30 Nov 2020Editorial Decision: Revise Minor
01 Dec 20203rd Revision Received
01 Dec 2020Review(s) Completed, Editorial Evaluation Pending
01 Dec 2020Editorial Decision: Revise Minor
17 Dec 20204th Revision Received
17 Dec 2020Review(s) Completed, Editorial Evaluation Pending
21 Dec 2020Editorial Decision: Accept